| Price | $66.82 |
| Year Range | $51.94 – $68.09 |
| Market Cap | $139B |
| PE Ratio | 15 |
| Industry | Drug Manufacturers |
What Is Bristol-Myers Squibb’s AI Stock Analysis?
Bristol-Myers Squibb’s AI stock analysis on AltIndex combines the company’s fundamentals, price technicals and 25+ alternative data signals — like hiring, web traffic, app downloads and online sentiment — into a single AI Score from 0 to 100 and a plain-English Buy, Hold or Sell read. Unlike a traditional analyst rating that updates a few times a year, the AI Score refreshes as new data arrives, so it tracks Bristol-Myers Squibb’s momentum in near-real time.
Bristol-Myers Squibb (BMY) has an AltIndex AI Score of 54/100, currently a Hold signal. The AI Score distills Bristol-Myers Squibb's fundamentals, price technicals and 25+ alternative data signals into a single 0–100 rating, so a rising score reflects strengthening data across the board and a falling score the opposite.
Bristol-Myers Squibb’s Full AI Analysis
Keep reading AltIndex’s full AI analysis of Bristol-Myers Squibb — the fundamental, technical and alternative-data breakdown and the recommendation.
Sign up to read the full analysisWhat’s Driving BMY’s AI Score?
Fundamentals
Revenue for the last quarter was $13B. This is an increase of 12.92% compared to the quarter before it, which is a positive sign of growth. Compared to the same quarter last year, there is an increase of 5.74%, suggesting positive year-over-year growth. Net income for the last quarter was $3.32B. This is an increase of 23.91% compared to the quarter before it, which is a positive sign of growth. Compared to the same quarter last year, there is an increase of 153.21%, suggesting positive year-over-year growth. Ebitda for the last quarter was $4.94B. This is an increase of 16.37% compared to the quarter before it, which is a positive sign of growth. Compared to the same quarter last year, there is an increase of 51.12%, suggesting positive year-over-year growth. The current P/E ratio is 15. This appears to be within a normal range, neither particularly high nor low.
See Bristol-Myers Squibb’s earnings and insider transactions.
Technicals
Today's stock price is $66.82. This is an increase of 1.41% compared to a month ago, indicating a positive short-term trend. Compared to a year ago, there is an increase of 48.49%, suggesting a positive long-term trend. The trend is bearish. The current SMA10 is $67.06, which is lower than the previous SMA10 of $67.17. This suggests a potential downward trend in price movement. The RSI is 24.8, indicating a potentially oversold (bullish) condition.
See the full technical analysis and price prediction.
Alternative data
Bristol-Myers Squibb has an estimated 636 open positions. This number is down by -22% in the last couple of months, indicating a company trying to improve its margins or cut costs. Not a great sign for a growing company. The business outlook among employees at Bristol-Myers Squibb is low (an estimate of only 44% of employees have a positive outlook), a concerning sign. Bristol-Myers Squibb has an estimate of 990,000 visitors to their webpage. The number of visitors is up by 15% in the last couple of months, a bullish trend as this can indicate can increase in customers.
Explore Bristol-Myers Squibb’s job postings, web traffic and app downloads.
Sentiment & social
Bristol-Myers Squibb has 24,000 followers on their Instagram page. The number of followers is up by 0% in the last couple of months, indicating an increased interest in the company. Bristol-Myers Squibb has 150,000 followers on their Twitter page. The number of followers is down by -0% in the last couple of months, indicating a loss in interest in the company.
Track Bristol-Myers Squibb’s market sentiment.
Frequently Asked Questions: Bristol-Myers Squibb AI Stock Analysis
Bristol-Myers Squibb's AltIndex AI Score is 54/100, currently a Hold signal. The AI Score blends fundamentals, technicals and 25+ alternative data signals into a single rating from 0 to 100.
AltIndex's AI Score model rates Bristol-Myers Squibb a Hold (54/100). This is a data-driven signal, not investment advice — review the breakdown above and combine it with your own research.
The AI Score is generated from fundamental data (earnings, valuation), technical indicators (price trend and momentum), and alternative data signals such as hiring, web traffic, app downloads and sentiment. AltIndex weighs these into a single 0-100 score; the exact weighting is proprietary.
AltIndex generates a complete written AI analysis of Bristol-Myers Squibb — company overview, fundamentals, technicals and alternative data, with a recommendation. See the BMY AI Score or sign up to read the full thesis.
